Editas Medicine, Inc.EDITEarnings & Financial Report
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
EDIT Q4 FY2025 Key Financial Metrics
Revenue
$24.7M
Gross Profit
N/A
Operating Profit
$-7.8M
Net Profit
$-5.6M
Gross Margin
N/A
Operating Margin
-31.3%
Net Margin
-22.7%
YoY Growth
-19.2%
EPS
$0.03
Editas Medicine, Inc. Q4 FY2025 Financial Summary
Editas Medicine, Inc. reported revenue of $24.7M (down 19.2% YoY) for Q4 FY2025, with a net profit of $-5.6M (up 87.6% YoY) (-22.7% margin).
Key Financial Metrics
| Total Revenue | $24.7M |
|---|---|
| Net Profit | $-5.6M |
| Gross Margin | N/A |
| Operating Margin | -31.3% |
| Report Period | Q4 FY2025 |
Editas Medicine, Inc. Annual Revenue by Year
Editas Medicine, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $40.5M).
Editas Medicine, Inc. Quarterly Revenue & Net Profit History
Editas Medicine, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $24.7M | -19.2% | $-5.6M | -22.7% |
| Q3 FY2025 | $7.5M | +12265.6% | $-25.1M | -333.0% |
| Q2 FY2025 | $3.6M | +597.5% | $-53.2M | -1487.8% |
| Q1 FY2025 | $4.7M | +310.4% | $-76.1M | -1633.5% |
| Q4 FY2024 | $30.6M | -49.0% | $-45.4M | -148.3% |
| Q3 FY2024 | $61.0K | -98.9% | $-62.1M | -101870.5% |
| Q2 FY2024 | $513.0K | -82.2% | $-67.6M | -13178.8% |
| Q1 FY2024 | $1.1M | -88.5% | $-62.0M | -5458.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $513000 | $61000 | $30.6M | $4.7M | $3.6M | $7.5M | $24.7M |
| YoY Growth | -88.5% | -82.2% | -98.9% | -49.0% | 310.4% | 597.5% | 12265.6% | -19.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $440.3M | $384.8M | $327.6M | $341.6M | $263.7M | $210.6M | $201.8M | $186.5M |
| Liabilities | $145.9M | $152.8M | $151.9M | $207.3M | $201.2M | $191.4M | $188.3M | $159.2M |
| Equity | $294.4M | $232.0M | $175.6M | $134.3M | $62.4M | $19.2M | $13.5M | $27.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-49.9M | $-57.1M | $-52.6M | $-50.8M | $-47.8M | $-50.2M | $-30.8M | $-36.4M |